tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Compass Therapeutics price target lowered to $10 from $12 at Guggenheim

Guggenheim lowered the firm’s price target on Compass Therapeutics (CMPX) to $10 from $12 and keeps a Buy rating on the shares. After the quarterly report, the firm updated its model to account for Q1 results and refined launch timing assumptions for tovecimig, the analyst tells investors.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1